Apogee Therapeutics Inc. $APGE Shares Sold by Granahan Investment Management LLC

Posted by George Bondi on Jun 17th, 2026

Granahan Investment Management LLC reduced its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) by 28.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 94,720 shares of the company’s stock after selling 37,680 shares during the quarter. Granahan Investment Management LLC’s holdings in Apogee Therapeutics were worth $7,149,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in APGE. Wellington Management Group LLP boosted its position in shares of Apogee Therapeutics by 24.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company’s stock worth $187,673,000 after acquiring an additional 917,991 shares in the last quarter. UBS Group AG boosted its position in shares of Apogee Therapeutics by 646.1% during the 3rd quarter. UBS Group AG now owns 799,465 shares of the company’s stock worth $31,763,000 after acquiring an additional 692,308 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Apogee Therapeutics by 27.3% during the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company’s stock worth $215,709,000 after acquiring an additional 612,193 shares in the last quarter. Remedium Capital Partners LLC acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth about $44,050,000. Finally, Jennison Associates LLC acquired a new position in shares of Apogee Therapeutics during the 4th quarter worth about $43,675,000. 79.04% of the stock is owned by institutional investors and hedge funds.

Apogee Therapeutics Stock Down 1.1%

Shares of NASDAQ APGE opened at $85.24 on Wednesday. The stock has a market cap of $5.28 billion, a PE ratio of -19.69 and a beta of 0.62. Apogee Therapeutics Inc. has a 52-week low of $34.34 and a 52-week high of $95.32. The business has a 50-day moving average price of $84.52 and a 200 day moving average price of $77.61.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.01. Sell-side analysts anticipate that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on APGE. Mizuho upped their price objective on Apogee Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Rothschild & Co Redburn began coverage on Apogee Therapeutics in a research report on Friday, May 1st. They set a “buy” rating and a $140.00 price objective for the company. Wedbush upped their target price on Apogee Therapeutics from $120.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, May 27th. BTIG Research reissued a “buy” rating and issued a $137.00 target price on shares of Apogee Therapeutics in a research report on Wednesday, May 27th. Finally, Canaccord Genuity Group upped their target price on Apogee Therapeutics from $89.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $114.56.

Read Our Latest Analysis on APGE

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $83.38, for a total transaction of $1,667,600.00. Following the completion of the sale, the chief executive officer directly owned 1,095,987 shares of the company’s stock, valued at $91,383,396.06. This represents a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $78.71, for a total value of $432,905.00. Following the sale, the insider directly owned 205,648 shares of the company’s stock, valued at approximately $16,186,554.08. This represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 76,500 shares of company stock valued at $6,323,295. Insiders own 24.30% of the company’s stock.

About Apogee Therapeutics

(Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.